5-HT6 pharmacology inconsistencies

被引：18

作者：

Borsini, Franco ^{[1
]}

Bordi, Fabio ^{[1
]}

Riccioni, Teresa ^{[1
]}

机构：

[1] Sigma Tau Ind Farmaceut Riunite SPA, I-00040 Rome, Italy

来源：

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR | 2011年 / 98卷 / 02期

关键词：

5HT6; Receptors; MRNA; Neurochemistry and behavior; RECEPTOR ANTAGONIST SB-399885; MEDIAL PREFRONTAL CORTEX; BRAIN-PENETRANT; RAT-BRAIN; ANTISENSE OLIGONUCLEOTIDES; COGNITIVE IMPAIRMENT; MEDICINAL CHEMISTRY; RADIOLIGAND BINDING; WATER MAZE; RO; 04-6790;

D O I：

10.1016/j.pbb.2010.12.021

中图分类号：

B84 [心理学]; C [社会科学总论]; Q98 [人类学];

学科分类号：

03 ; 0303 ; 030303 ; 04 ; 0402 ;

摘要：

5-HT6 receptors are relatively recently-discovered receptors. After an uncertain beginning, where results were ambiguous, findings are now apparently more congruent. Nevertheless, discrepancies still exist. The aim of the present manuscript is to point out some of these discrepancies, in order to reflect on the current status of the field of the 5-HT6 receptor neuropharmacology, and where the field should move next. Examples of 5-HT6 receptor ligand-induced changes in behavior, neurochemistry and binding highlight areas where discrepancies remain and further experimental attention is needed. Possible methodological as well as conceptual issues underlying the inconsistencies are considered in an effort to increase awareness of the need for more thorough consideration of these aspects in future research. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：169 / 172

页数：4

共 67 条

[31] Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling [J].

Hirst, WD ;

Abrahamsen, B ;

Blaney, FE ;

Calver, AR ;

Aloj, L ;

Price, GW ;

Medhurst, AD .

MOLECULAR PHARMACOLOGY, 2003, 64 (06) :1295-1308

[32] Medicinal chemistry strategies to 5-HT6 receptor ligands as potential cognitive enhancers and antiobesity agents [J].

Holenz, J ;

Pauwels, PJ ;

Díaz, JL ;

Mercè, R ;

Codony, X ;

Buschmann, H .

DRUG DISCOVERY TODAY, 2006, 11 (7-8) :283-299

[33] 6-bicyclopiperazinyl-1-arylsulfonylindoles and 6-bicyclopiperidinyl-1-arylsulfonylindoles derivatives as novel, potent, and selective 5-HT6 receptor antagonists [J].

Isaac, M ;

Slassi, A ;

Xin, T ;

MacLean, N ;

Wilson, J ;

McCallum, K ;

Wang, H ;

Demchyshyn, L .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (15) :1719-1721

[34] 8-Sulfonyl-substituted tetrahydro-1H-pyrido[4,3-b]indoles as 5-HT6 receptor antagonists [J].

Ivachtchenko, Alexandre V. ;

Mitkin, Oleg D. ;

Tkachenko, Sergey E. ;

Okun, Ilya M. ;

Kysil, Volodymyr M. .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (02) :782-789

[35]

Johnson CN, 2008, CURR OPIN DRUG DISC, V11, P642

[36]

Kendall I., 2010, Psychopharmacology

[37] 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex [J].

Lacroix, LP ;

Dawson, LA ;

Hagan, JJ ;

Heidbreder, CA .

SYNAPSE, 2004, 51 (02) :158-164

[38]

Lane HY, 2008, J PSYCHIATR NEUROSCI, V33, P47

[39] 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus [J].

Li, Zhu ;

Huang, Mei ;

Prus, Adam J. ;

Dai, Fin ;

Meltzer, Herbert Y. .

BRAIN RESEARCH, 2007, 1134 (01) :70-78

[40] An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning [J].

Lindner, MD ;

Hodges, DB ;

Hogan, JB ;

Orie, AF ;

Corsa, JA ;

Barten, DM ;

Polson, C ;

Robertson, BJ ;

Guss, VL ;

Gillman, KW ;

Starrett, JE ;

Gribkoff, VK .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (02) :682-691

← 1 2 3 4 5 6 7 →